Please Scroll Down to See Forums Below which legal supplement works best for fat loss for some one that is considerably over weight( i know diet is most important but i also know there are some supplementsthat will work incredibly well for overweight people and some that will only help with the finishing touches. I am considering a t2 and an nyc stack but would like to know if there are better options for someone that is overweight. again I know diet comes first but am positive i want something to supplement my efforts
fat loss for big guy
- Thread starter elg123
- Start date
I was once really over weight...Very long story short:
If I were you I'd concentrate on getting the diet PERFECT, and developing a very consistent moderate cardio routine.
I did a lot of things that, essentially, modified my metabolisim (NYC, Triax, ECA, T3). All of them had temporary benefits, but since I had never really learned how my body "worked" and how to modify my metabolism via diet and proper cardio, etc, I was never EVER able to hold onto those gains (or loses I guess). ONly more recently, after going through the painful process of actually figuring my body out, am I now able to use such supps succesfully.
BTW: I started at over 23% bf 10 years ago, bounced around in the 14% to 20% range for 6 years while using ECA, NYC, Triax. Finally, 2yrs ago, decided to "just do it right" and got down to 8% on my own. I was 30y/o and finally in the best shape of my life. I managed to cut my bf in half in 7mo something I failed to do in 8 years with supps... Now, when I want to be 6% or so I will use supps....
If I were you I'd concentrate on getting the diet PERFECT, and developing a very consistent moderate cardio routine.
I did a lot of things that, essentially, modified my metabolisim (NYC, Triax, ECA, T3). All of them had temporary benefits, but since I had never really learned how my body "worked" and how to modify my metabolism via diet and proper cardio, etc, I was never EVER able to hold onto those gains (or loses I guess). ONly more recently, after going through the painful process of actually figuring my body out, am I now able to use such supps succesfully.
BTW: I started at over 23% bf 10 years ago, bounced around in the 14% to 20% range for 6 years while using ECA, NYC, Triax. Finally, 2yrs ago, decided to "just do it right" and got down to 8% on my own. I was 30y/o and finally in the best shape of my life. I managed to cut my bf in half in 7mo something I failed to do in 8 years with supps... Now, when I want to be 6% or so I will use supps....
Last edited:
SirWanksalot
New member
Instead of spending money on Biotests T2 or NYC for that matter, spend some of that money on Lyle's latest book (i'm sounding like a broken record) BROMOCRITINE. Once you read it, spend the other on the drug bromocriptine itself. Always use science when possible and avoid the hype of advertisements.
If your big or obese then using the drug Meridia and bromocriptine together could work very well for your goal...
SirWanksAlot
If your big or obese then using the drug Meridia and bromocriptine together could work very well for your goal...
SirWanksAlot
macrophage69alpha
New member
think that most will find selegine hcl preferable to bromocriptine
SirWanksalot
New member
T-Mag did a review on the book
http://www.testosterone.net/articles/214use2.html
A Good Book
If you've ever researched ketogenic diets, you've probably heard the name Lyle McDonald. I've known Lyle for years and for sure he's a quirky, eccentric, megalomaniac, and occasionally a serious pain in the ass. All of that notwithstanding, Lyle is still quite an expert when it comes to CKD/TKD and ketogenesis.
Well, Lyle has a new book out and I was fortunate enough to review this book before it was published and sold. The information contained in Bromocriptine — An Old Drug with New Uses (Lyle's new fat loss codex) may revolutionize the way we look at fat loss, dieting, and supplementing for both.
Bromocriptine has been around for over thirty years as a prescription treatment for Parkinson's Disease and other associated neurological deficits. It (and its newer analogs like cabergoline) has a solid track record in humans. It's a drug I'd have little reservations about using in low dosages for fat loss over extended periods of time because of its impressive safety profile. In fact, I'd certainly pick bromocriptine over clenbuterol (which I feel is useless), liothyronine, and the smorgasbord of other "diet drugs" that have become too commonplace in today's bodybuilding arsenal.
Lyle takes fat loss in an entirely new direction with his book. Traditional fat loss mantra maintains we need to stimulate the beta 1-2-3 and/or alpha 1-2 receptors to induce lipolysis. Either that or we have to tweak thyroid hormone levels up high enough to crank up basal metabolic rate and core body temperature. But Lyle looks at fat loss through a different perspective, that of the dopamine receptors (DA-1 and DA-2) and the current crop of dopaminergic agonists.
His book is logical, methodical, and in my opinion, right on the money. If you're serious about losing fat (and more importantly, keeping it off), this is a book worth looking into. Currently, Lyle's book is only available as an e-book but I hope that a paper edition will be available sooner rather than later. Check it out.
http://www.testosterone.net/articles/214use2.html
A Good Book
If you've ever researched ketogenic diets, you've probably heard the name Lyle McDonald. I've known Lyle for years and for sure he's a quirky, eccentric, megalomaniac, and occasionally a serious pain in the ass. All of that notwithstanding, Lyle is still quite an expert when it comes to CKD/TKD and ketogenesis.
Well, Lyle has a new book out and I was fortunate enough to review this book before it was published and sold. The information contained in Bromocriptine — An Old Drug with New Uses (Lyle's new fat loss codex) may revolutionize the way we look at fat loss, dieting, and supplementing for both.
Bromocriptine has been around for over thirty years as a prescription treatment for Parkinson's Disease and other associated neurological deficits. It (and its newer analogs like cabergoline) has a solid track record in humans. It's a drug I'd have little reservations about using in low dosages for fat loss over extended periods of time because of its impressive safety profile. In fact, I'd certainly pick bromocriptine over clenbuterol (which I feel is useless), liothyronine, and the smorgasbord of other "diet drugs" that have become too commonplace in today's bodybuilding arsenal.
Lyle takes fat loss in an entirely new direction with his book. Traditional fat loss mantra maintains we need to stimulate the beta 1-2-3 and/or alpha 1-2 receptors to induce lipolysis. Either that or we have to tweak thyroid hormone levels up high enough to crank up basal metabolic rate and core body temperature. But Lyle looks at fat loss through a different perspective, that of the dopamine receptors (DA-1 and DA-2) and the current crop of dopaminergic agonists.
His book is logical, methodical, and in my opinion, right on the money. If you're serious about losing fat (and more importantly, keeping it off), this is a book worth looking into. Currently, Lyle's book is only available as an e-book but I hope that a paper edition will be available sooner rather than later. Check it out.
macrophage69alpha
New member
uuuhmmm..
STILL, regardless, most people will find selegine hcl preferable and likely as effective.. and (i think) cheaper..
STILL, regardless, most people will find selegine hcl preferable and likely as effective.. and (i think) cheaper..
macrophage69alpha
New member
btw- be prepared for increased paranoia.. which all dopaminergic drugs tend to cause.. usually the effects become annoying only at higher dosages
SirWanksalot
New member
New Study on Bromocriptine
Eur J Endocrinol 2002 Jul;147(1):77-84
Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V.
Institute of Endocrinology, University Clinical Center, Belgrade, Yugoslavia.
OBJECTIVE: It has recently been shown that increased body weight is associated with prolactinomas and that weight loss occurs with normalization of prolactin levels. On the other hand, decreased dopaminergic tone in humans is well correlated with obesity. The objective of this study was to correlate changes in prolactin levels with leptin and body mass index (BMI) in patients with prolactinomas treated with the long-acting dopamine agonist
bromocriptine (BC).
METHODS: Eleven female and twelve male patients, aged 36.7+/-2.6 years with BMI in males of 30.4+/-1.7 kg/m(2) and in females of 24.4+/-1.2 kg/m(2), were evaluated after 1 and 6 months and 11 patients were further evaluated after 2 years of BC therapy. Plasma prolactin is presented as the mean of four samples taken daily. Serum leptin was determined in the pooled serum from three samples taken at 15-min intervals at 0800 h after an overnight fast. Multivariate linear regression and repeated measures analysis of covariance were used.
RESULTS: In males, pretreatment prolactin levels were 71 362+/-29 912 mU/l while leptin levels were 14.9+/-1.8 &mgr;g/l. In females, pretreatment prolactin levels were 11 395+/-5839 mU/l and leptin levels were 16.7+/-2.5 &mgr;g/l. The sexual dimorphism of serum leptin levels at initial presentation was preserved after adjusting for BMI and prolactin-induced hypogonadism. After 1 month of therapy, prolactin levels significantly decreased (males: 17 618+/-8736 mU/l, females: 3686+/-2231; P<0.05), BMI did not change (males: 30.2+/-1.7 kg/m(2), females: 24.1+/-1.2 kg/m(2); P>0.05), while serum leptin levels decreased (males: 12.5+/-1.5 &mgr;g/l, females: 13.6+/-2.1 &mgr;g/l; P<0.05). After 6 months of treatment, prolactin further decreased (males: 3456+/-2101 mU/l, females: 677+/-360 mU/l; P<0.05) as did BMI (males: 28.6+/-1.6 kg/m(2), females 23.1+/-1.0 kg/m(2); P<0.05). The difference was more pronounced in male patients. Leptin levels were 12.8+/-2.8 &mgr;g/l in males and 12.9+/-1.8 &mgr;g/l in females (P<0.05). After 2 years of BC treatment, prolactin levels were near normal (males: 665+/-439 mU/l, females 447+/-130 mU/l; P<0.05) and BMI remained 26.5+/-1.9 kg/m(2) for males and 23.6+/-0.8 kg/m(2) for females (P<0.05). Leptin levels were 9.5+/-2.2 &mgr;g/l in males and 18.7+/-3.1 &mgr;g/l in females (P<0.05). There was a gradual increase in the gender difference in serum leptin levels over time. Changes in serum leptin levels significantly correlated with changes in BMI (r=0.844, P<0.001) but did not correlate with changes in plasma prolactin levels after 1 month (r=0.166), 6 months (r=0.313) and 2 years (r=0.234, P>0.05). CONCLUSION: The long-acting dopamine agonist BC, by increasing dopaminergic tone, may influence body weight and likely body composition by mechanisms in addition to reducing hyperprolactinemia in patients with prolactinomas.
Eur J Endocrinol 2002 Jul;147(1):77-84
Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V.
Institute of Endocrinology, University Clinical Center, Belgrade, Yugoslavia.
OBJECTIVE: It has recently been shown that increased body weight is associated with prolactinomas and that weight loss occurs with normalization of prolactin levels. On the other hand, decreased dopaminergic tone in humans is well correlated with obesity. The objective of this study was to correlate changes in prolactin levels with leptin and body mass index (BMI) in patients with prolactinomas treated with the long-acting dopamine agonist
bromocriptine (BC).
METHODS: Eleven female and twelve male patients, aged 36.7+/-2.6 years with BMI in males of 30.4+/-1.7 kg/m(2) and in females of 24.4+/-1.2 kg/m(2), were evaluated after 1 and 6 months and 11 patients were further evaluated after 2 years of BC therapy. Plasma prolactin is presented as the mean of four samples taken daily. Serum leptin was determined in the pooled serum from three samples taken at 15-min intervals at 0800 h after an overnight fast. Multivariate linear regression and repeated measures analysis of covariance were used.
RESULTS: In males, pretreatment prolactin levels were 71 362+/-29 912 mU/l while leptin levels were 14.9+/-1.8 &mgr;g/l. In females, pretreatment prolactin levels were 11 395+/-5839 mU/l and leptin levels were 16.7+/-2.5 &mgr;g/l. The sexual dimorphism of serum leptin levels at initial presentation was preserved after adjusting for BMI and prolactin-induced hypogonadism. After 1 month of therapy, prolactin levels significantly decreased (males: 17 618+/-8736 mU/l, females: 3686+/-2231; P<0.05), BMI did not change (males: 30.2+/-1.7 kg/m(2), females: 24.1+/-1.2 kg/m(2); P>0.05), while serum leptin levels decreased (males: 12.5+/-1.5 &mgr;g/l, females: 13.6+/-2.1 &mgr;g/l; P<0.05). After 6 months of treatment, prolactin further decreased (males: 3456+/-2101 mU/l, females: 677+/-360 mU/l; P<0.05) as did BMI (males: 28.6+/-1.6 kg/m(2), females 23.1+/-1.0 kg/m(2); P<0.05). The difference was more pronounced in male patients. Leptin levels were 12.8+/-2.8 &mgr;g/l in males and 12.9+/-1.8 &mgr;g/l in females (P<0.05). After 2 years of BC treatment, prolactin levels were near normal (males: 665+/-439 mU/l, females 447+/-130 mU/l; P<0.05) and BMI remained 26.5+/-1.9 kg/m(2) for males and 23.6+/-0.8 kg/m(2) for females (P<0.05). Leptin levels were 9.5+/-2.2 &mgr;g/l in males and 18.7+/-3.1 &mgr;g/l in females (P<0.05). There was a gradual increase in the gender difference in serum leptin levels over time. Changes in serum leptin levels significantly correlated with changes in BMI (r=0.844, P<0.001) but did not correlate with changes in plasma prolactin levels after 1 month (r=0.166), 6 months (r=0.313) and 2 years (r=0.234, P>0.05). CONCLUSION: The long-acting dopamine agonist BC, by increasing dopaminergic tone, may influence body weight and likely body composition by mechanisms in addition to reducing hyperprolactinemia in patients with prolactinomas.
